- Serán BioScience has completed two of three new buildings for its 100,000 ft² commercial manufacturing campus in Bend, Oregon.
- The project, supported by Bain Capital Life Sciences and Vivo Capital, expands the company’s end-to-end CDMO services for small-molecule therapeutics.
Serán BioScience, a science-driven drug development partner, has completed two of three new buildings and begun construction of the third at its 100,000 ft² commercial manufacturing campus in Bend, Oregon. The site includes a 50,000 ft² manufacturing facility and an adjacent 50,000 ft² space for specialised packaging and supply chain operations.
The expansion follows new investment from Bain Capital Life Sciences in September 2024, alongside continued support from Vivo Capital. The project enhances Serán’s capabilities to provide fully integrated contract manufacturing support for complex oral solid dosage forms, spanning from first-in-human (FiH) trials to commercial-scale production.
The U.S. facility is designed for the commercial production of non-sterile solid dose products and will operate in compliance with global regulatory standards. It focuses on advanced formulation techniques, including spray drying, particle engineering, and drug delivery optimisation.
“Our investment in commercial manufacturing capabilities is a direct response to the evolving needs of our clients. Modern medicines are increasingly complex and thus require specialised development and manufacturing.”
Dan Smithey, CEO of Serán BioScience
Two newly completed warehouse and light manufacturing buildings, totalling 50,000 ft², will support materials management, packaging, labelling, and other logistics functions. Located near Serán’s existing 90,000 ft² clinical development campus, the new site will integrate with its current operations to ensure seamless scale-up and supply chain reliability.
